Pediatric exclusivity and other contemporary regulatory changes: impact on pediatric drug study, labeling and safety
Kevin D. Hill, Phillip Brian Smith, Michael Cohen‐Wolkowiez, Daniel Kelly Benjamin, Jennifer S. Li · Clinical Investigation · 2013
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Clinical Investigation · OMICS Publishing Group · article · 2013
Abstract
Historically, most drugs have been used ‘off-label’ in children due to a lack of specific information on dosing, safety and efficacy. This practice risks adverse events, leading to serious public health consequences. Regulatory changes have attempted to address such issues by mandating and incentivizing the study of drugs in children. By all accounts, these regulatory changes have been enormously successful in stimulating >400 pediatric clinical trials enrolling >170,000 children over the last 5 years. These trials and others conducted over the preceding 15 years have resulted in >400 pediatric-specific labeling changes.
While these labeling changes have improved pediatric drug safety, critics voice continuing concerns about the ‘financial windfall’ for industry, relative lack of study of off-patent agents and continued neglect of several important pediatric subpopulations (e.g., neonates).
Open the resolved locator · 10.4155/cli.12.154
Metadata licence: OpenAlex metadata (CC0)